[go: up one dir, main page]

PE20120592A1 - Metodo con biomarcadores para el seguimiento de un tratamiento - Google Patents

Metodo con biomarcadores para el seguimiento de un tratamiento

Info

Publication number
PE20120592A1
PE20120592A1 PE2011001619A PE2011001619A PE20120592A1 PE 20120592 A1 PE20120592 A1 PE 20120592A1 PE 2011001619 A PE2011001619 A PE 2011001619A PE 2011001619 A PE2011001619 A PE 2011001619A PE 20120592 A1 PE20120592 A1 PE 20120592A1
Authority
PE
Peru
Prior art keywords
treatment
disease
biomarker
biomarkers
monitoring
Prior art date
Application number
PE2011001619A
Other languages
English (en)
Inventor
Tokuzo Arao
Kanae Kudo
Kazuhiko Nakagawa
Kazuto Nishio
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20120592A1 publication Critical patent/PE20120592A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN METODO O SISTEMA PARA EL SEGUIMIENTO DE UN TRATAMIENTO IMPLICADO CON LA PROLIFERACION CELULAR, CON LA SAL MONOETANOSULFONATO DE 3-Z-[1-(4-(N-((4-METIL-PIPERAZIN-1-IL)-METILCARBONIL)-N-METILAMINO)-ANILINO)-1-FENIL-METILEN]-6-METOXICARBONIL-2-INDOLINONA QUE COMPRENDE DETERMINAR SI UNA MUESTRA DE SANGRE COMPRENDE UN BIOMARCADOR EN UNA CANTIDAD QUE ES INDICATIVA PARA DICHO TRATAMIENTO. DICHO BIOMARCADOR INDICA UN CAMBIO EN LA EXPRESION O ESTADO DE UNA PROTEINA O EN LA CANTIDAD DE CELULAS ESPECIFICAS QUE SE CORRELACIONA CON EL RIESGO O PROGRESION DE UNA ENFERMEDAD O CON LA SUSCEPTIBILIDAD DE LA ENFERMEDAD A UN TRATAMIENTO DADO. REFERIDA ADEMAS A UN KIT DE DIAGNOSTICO QUE COMPRENDE EL MEDIO PARA REALIZAR DICHO METODO
PE2011001619A 2009-03-12 2010-03-11 Metodo con biomarcadores para el seguimiento de un tratamiento PE20120592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
PE20120592A1 true PE20120592A1 (es) 2012-06-09

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001619A PE20120592A1 (es) 2009-03-12 2010-03-11 Metodo con biomarcadores para el seguimiento de un tratamiento

Country Status (24)

Country Link
US (1) US8802384B2 (es)
EP (1) EP2406628A1 (es)
JP (1) JP5667581B2 (es)
KR (1) KR20110137307A (es)
CN (1) CN102334030A (es)
AR (1) AR076113A1 (es)
AU (1) AU2010223256B2 (es)
BR (1) BRPI1011688A2 (es)
CA (1) CA2755055A1 (es)
CL (1) CL2011002260A1 (es)
CO (1) CO6430497A2 (es)
EA (1) EA201101300A1 (es)
EC (1) ECSP11011323A (es)
IL (1) IL214747A0 (es)
MA (1) MA33120B1 (es)
MX (1) MX2011009482A (es)
NZ (1) NZ594843A (es)
PE (1) PE20120592A1 (es)
SG (1) SG174324A1 (es)
TN (1) TN2011000457A1 (es)
TW (1) TW201100802A (es)
UA (1) UA107789C2 (es)
UY (1) UY32482A (es)
WO (1) WO2010103058A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100254A1 (es) * 2008-06-06 2010-04-21 Boehringer Ingelheim Int Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ATE475884T1 (de) 2006-04-18 2010-08-15 Wellstat Biologics Corp Detektion von zirkulierenden endothelzellen
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
JP2010502209A (ja) * 2006-09-07 2010-01-28 アストラゼネカ アクチボラグ Ｒｅｔレセプターチロシンキナーゼを標的とする薬剤による治療のために患者を評価する方法
US20100234381A1 (en) 2007-04-13 2010-09-16 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer

Also Published As

Publication number Publication date
MX2011009482A (es) 2011-09-27
JP2012520446A (ja) 2012-09-06
ECSP11011323A (es) 2011-10-31
US8802384B2 (en) 2014-08-12
TN2011000457A1 (en) 2013-03-27
WO2010103058A1 (en) 2010-09-16
AU2010223256B2 (en) 2014-08-21
EA201101300A1 (ru) 2012-04-30
BRPI1011688A2 (pt) 2016-03-22
AU2010223256A1 (en) 2011-09-15
IL214747A0 (en) 2011-11-30
SG174324A1 (en) 2011-10-28
CA2755055A1 (en) 2010-09-16
AR076113A1 (es) 2011-05-18
JP5667581B2 (ja) 2015-02-12
UA107789C2 (en) 2015-02-25
MA33120B1 (fr) 2012-03-01
CO6430497A2 (es) 2012-04-30
TW201100802A (en) 2011-01-01
NZ594843A (en) 2014-03-28
US20100233705A1 (en) 2010-09-16
EP2406628A1 (en) 2012-01-18
CL2011002260A1 (es) 2012-03-23
KR20110137307A (ko) 2011-12-22
UY32482A (es) 2010-10-29
CN102334030A (zh) 2012-01-25

Similar Documents

Publication Publication Date Title
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE554389T1 (de) Apex als marker für lungenkrebs
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
MX356986B (es) Metodo para detectar aductos de nucleosomas.
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
EA201370063A1 (ru) Фосфолипидом рака
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
MX2019010563A (es) Desarrollo y uso de sondas fluorescentes de bilirrubina sin enlazar.
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
ES2845150T3 (es) Diagnóstico de pancreatitis aguda (PA) mediante la detección de glicoproteína 2 isoforma alfa (GP2A)
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
EP2074427A4 (en) Diagnostic biomolecule(s)
PE20160657A1 (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto
MX380889B (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson.
AR105379A1 (es) Dispositivo para detectar proteínas mal plegadas y sus métodos de uso
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.

Legal Events

Date Code Title Description
FC Refusal